Acquisitions Management Operations Branch, NIAID, 6700-B Rockledge Drive, Room 1130, Bethesda, MD 20892-7605

R -- PRODUCTION AND SAFETY TESTING OF CLINICAL GRADE ADENOVIRUS VECTORS FOR VACCINES SOL NIAID-VRC-00-60 DUE 062600 POC Donna Baker, Contract Specialist or Karin Eddy, Contracting Officer, 301-496-3878 The Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID) intends to procure from IntroGene, B.V., from Leiden, the Netherlands, clinical grade adenovirus constructs using the PerC.6 cell line. The goal of the work is to provide adenoviral vector material that will result in the ability of the Vaccine Research Center, NIAID and other NIH staff to conduct clinical vaccine trials with adenoviral materials that safisfy and conform to all current US Food and Drug Administration rules and regulations regarding these vaccine related materials, including written documentation. This product can only be obtained from IntroGene because they have proprietary rights to the cell line required for GMP vector production. SEE NUMBERED Note 22 Posted 05/04/00 (W-SN451719). (0125)

Loren Data Corp. http://www.ld.com (SYN# 0082 20000508\R-0006.SOL)